1. Home
  2. HTH vs RARE Comparison

HTH vs RARE Comparison

Compare HTH & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hilltop Holdings Inc.

HTH

Hilltop Holdings Inc.

HOLD

Current Price

$36.89

Market Cap

2.2B

Sector

Finance

ML Signal

HOLD

Logo Ultragenyx Pharmaceutical Inc.

RARE

Ultragenyx Pharmaceutical Inc.

HOLD

Current Price

$23.40

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HTH
RARE
Founded
1998
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.3B
IPO Year
2004
2014

Fundamental Metrics

Financial Performance
Metric
HTH
RARE
Price
$36.89
$23.40
Analyst Decision
Hold
Strong Buy
Analyst Count
2
19
Target Price
$34.00
$73.11
AVG Volume (30 Days)
216.6K
4.0M
Earning Date
01-29-2026
02-12-2026
Dividend Yield
1.95%
N/A
EPS Growth
53.28
N/A
EPS
2.50
N/A
Revenue
$1,259,399,000.00
$630,598,000.00
Revenue This Year
N/A
$19.68
Revenue Next Year
$1.64
$19.44
P/E Ratio
$14.75
N/A
Revenue Growth
7.66
20.63
52 Week Low
$27.35
$18.41
52 Week High
$37.04
$46.50

Technical Indicators

Market Signals
Indicator
HTH
RARE
Relative Strength Index (RSI) 69.65 38.36
Support Level $35.18 $22.00
Resistance Level $35.93 $24.65
Average True Range (ATR) 0.70 1.28
MACD 0.20 0.19
Stochastic Oscillator 85.99 44.59

Price Performance

Historical Comparison
HTH
RARE

About HTH Hilltop Holdings Inc.

Hilltop Holdings Inc is a Dallas-based financial holding company. The Company has two primary business units, PCC (banking and mortgage origination) and Securities Holdings (broker-dealer). The banking segment includes the operations of the Bank. The banking segment provides business and consumer banking services from offices located throughout Texas and generates revenue from its portfolio of earning assets. The broker-dealer segment includes the operations of Securities Holdings, which operates through its wholly owned subsidiaries Hilltop Securities, Asset Managment LLC, etc. The broker-dealer segment generates a majority of its revenues from fees and commissions earned from investment advisory and securities brokerage services. Majority of revenue is from Banking Segment.

About RARE Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Share on Social Networks: